Regeneron Plunges 6.86% on Q1 Revenue Miss

On April 29, 2025, Regeneron's stock experienced a significant drop of 6.86% in pre-market trading, reflecting investor concerns and market sentiment.

Regeneron's first-quarter sales for 2025 fell short of Wall Street's expectations, with a 3.7% year-over-year decline to $3.03 billion. This shortfall in revenue has raised concerns about the company's financial performance and its ability to meet market expectations.

Despite the revenue miss, Regeneron reported a 12% increase in GAAP net income for Q1 2025, reaching $809 million. However, the company's non-GAAP net income decreased by 17%, which may indicate underlying challenges in its operational efficiency or cost management.

Regeneron's recent earnings report highlighted the company's ongoing efforts to innovate and expand its product portfolio. The company announced the presentation of 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, focusing on the real-world use and efficacy of EYLEA HD in treating wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. These presentations aim to reinforce the positive outcomes seen in pivotal trials and provide early insights into the drug's effectiveness in clinical practice.